Paraneoplastic Syndromes and Thymic Malignancies

An Examination of the International Thymic Malignancy Interest Group Retrospective Database

Sukhmani K. Padda, Xiaopan Yao, Alberto Antonicelli, Jonathan W. Riess, Yue Shang, Joseph B. Shrager, Robert Korst, Frank Detterbeck, James Huang, Bryan M. Burt, Heather A. Wakelee, Sunil Badve

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction: Thymic epithelial tumors (TETs) are associated with paraneoplastic/autoimmune (PN/AI) syndromes. Myasthenia gravis is the most common PN/AI syndrome associated with TETs. Methods: The International Thymic Malignancy Interest Group retrospective database was examined to determine (1) baseline and treatment characteristics associated with PN/AI syndromes and (2) the prognostic role of PN/AI syndromes for patients with TETs. The competing risks model was used to estimate cumulative incidence of recurrence (CIR) and the Kaplan-Meier method was used to calculate overall survival (OS). A Cox proportional hazards model was used for multivariate analysis. Results: A total of 6670 patients with known PN/AI syndrome status from 1951 to 2012 were identified. PN/AI syndromes were associated with younger age, female sex, thymoma histologic type, earlier stage, and an increased rate of total thymectomy and complete resection status. There was a statistically significant lower CIR in the group with a PN/AI syndrome than in the group without a PN/AI syndrome (10-year CIR 17.3% versus 21.2%, respectively [p = 0.0003]). The OS was improved in the group with a PN/AI syndrome compared to the group without a PN/AI syndrome (median OS 21.6 years versus 17.0 years, respectively [hazard ratio = 0.63, 95% confidence interval: 0.54–0.74, p < 0.0001]). However, in the multivariate model for recurrence-free survival and OS, PN/AI syndrome was not an independent prognostic factor. Discussion: Previously, there have been mixed data regarding the prognostic role of PN/AI syndromes for patients with TETs. Here, using the largest data set in the world for TETs, PN/AI syndromes were associated with favorable features (i.e., earlier stage and complete resection status) but were not an independent prognostic factor for patients with TETs.

Original languageEnglish (US)
Pages (from-to)e33-e34
JournalJournal of Thoracic Oncology
Volume13
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Paraneoplastic Syndromes
Public Opinion
Databases
Neoplasms
Survival
Recurrence
Incidence
Thymectomy
Thymoma
Myasthenia Gravis
Proportional Hazards Models
Thymic epithelial tumor

Keywords

  • Myasthenia gravis
  • Paraneoplastic
  • Thymic carcinoma
  • Thymic epithelial tumor
  • Thymoma

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Paraneoplastic Syndromes and Thymic Malignancies : An Examination of the International Thymic Malignancy Interest Group Retrospective Database. / Padda, Sukhmani K.; Yao, Xiaopan; Antonicelli, Alberto; Riess, Jonathan W.; Shang, Yue; Shrager, Joseph B.; Korst, Robert; Detterbeck, Frank; Huang, James; Burt, Bryan M.; Wakelee, Heather A.; Badve, Sunil.

In: Journal of Thoracic Oncology, Vol. 13, No. 3, 01.03.2018, p. e33-e34.

Research output: Contribution to journalArticle

Padda, SK, Yao, X, Antonicelli, A, Riess, JW, Shang, Y, Shrager, JB, Korst, R, Detterbeck, F, Huang, J, Burt, BM, Wakelee, HA & Badve, S 2018, 'Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database', Journal of Thoracic Oncology, vol. 13, no. 3, pp. e33-e34. https://doi.org/10.1016/j.jtho.2017.11.118
Padda, Sukhmani K. ; Yao, Xiaopan ; Antonicelli, Alberto ; Riess, Jonathan W. ; Shang, Yue ; Shrager, Joseph B. ; Korst, Robert ; Detterbeck, Frank ; Huang, James ; Burt, Bryan M. ; Wakelee, Heather A. ; Badve, Sunil. / Paraneoplastic Syndromes and Thymic Malignancies : An Examination of the International Thymic Malignancy Interest Group Retrospective Database. In: Journal of Thoracic Oncology. 2018 ; Vol. 13, No. 3. pp. e33-e34.
@article{93d19a2405fc4a4a8ee78aa71db25f9b,
title = "Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database",
abstract = "Introduction: Thymic epithelial tumors (TETs) are associated with paraneoplastic/autoimmune (PN/AI) syndromes. Myasthenia gravis is the most common PN/AI syndrome associated with TETs. Methods: The International Thymic Malignancy Interest Group retrospective database was examined to determine (1) baseline and treatment characteristics associated with PN/AI syndromes and (2) the prognostic role of PN/AI syndromes for patients with TETs. The competing risks model was used to estimate cumulative incidence of recurrence (CIR) and the Kaplan-Meier method was used to calculate overall survival (OS). A Cox proportional hazards model was used for multivariate analysis. Results: A total of 6670 patients with known PN/AI syndrome status from 1951 to 2012 were identified. PN/AI syndromes were associated with younger age, female sex, thymoma histologic type, earlier stage, and an increased rate of total thymectomy and complete resection status. There was a statistically significant lower CIR in the group with a PN/AI syndrome than in the group without a PN/AI syndrome (10-year CIR 17.3{\%} versus 21.2{\%}, respectively [p = 0.0003]). The OS was improved in the group with a PN/AI syndrome compared to the group without a PN/AI syndrome (median OS 21.6 years versus 17.0 years, respectively [hazard ratio = 0.63, 95{\%} confidence interval: 0.54–0.74, p < 0.0001]). However, in the multivariate model for recurrence-free survival and OS, PN/AI syndrome was not an independent prognostic factor. Discussion: Previously, there have been mixed data regarding the prognostic role of PN/AI syndromes for patients with TETs. Here, using the largest data set in the world for TETs, PN/AI syndromes were associated with favorable features (i.e., earlier stage and complete resection status) but were not an independent prognostic factor for patients with TETs.",
keywords = "Myasthenia gravis, Paraneoplastic, Thymic carcinoma, Thymic epithelial tumor, Thymoma",
author = "Padda, {Sukhmani K.} and Xiaopan Yao and Alberto Antonicelli and Riess, {Jonathan W.} and Yue Shang and Shrager, {Joseph B.} and Robert Korst and Frank Detterbeck and James Huang and Burt, {Bryan M.} and Wakelee, {Heather A.} and Sunil Badve",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.jtho.2017.11.118",
language = "English (US)",
volume = "13",
pages = "e33--e34",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "3",

}

TY - JOUR

T1 - Paraneoplastic Syndromes and Thymic Malignancies

T2 - An Examination of the International Thymic Malignancy Interest Group Retrospective Database

AU - Padda, Sukhmani K.

AU - Yao, Xiaopan

AU - Antonicelli, Alberto

AU - Riess, Jonathan W.

AU - Shang, Yue

AU - Shrager, Joseph B.

AU - Korst, Robert

AU - Detterbeck, Frank

AU - Huang, James

AU - Burt, Bryan M.

AU - Wakelee, Heather A.

AU - Badve, Sunil

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Introduction: Thymic epithelial tumors (TETs) are associated with paraneoplastic/autoimmune (PN/AI) syndromes. Myasthenia gravis is the most common PN/AI syndrome associated with TETs. Methods: The International Thymic Malignancy Interest Group retrospective database was examined to determine (1) baseline and treatment characteristics associated with PN/AI syndromes and (2) the prognostic role of PN/AI syndromes for patients with TETs. The competing risks model was used to estimate cumulative incidence of recurrence (CIR) and the Kaplan-Meier method was used to calculate overall survival (OS). A Cox proportional hazards model was used for multivariate analysis. Results: A total of 6670 patients with known PN/AI syndrome status from 1951 to 2012 were identified. PN/AI syndromes were associated with younger age, female sex, thymoma histologic type, earlier stage, and an increased rate of total thymectomy and complete resection status. There was a statistically significant lower CIR in the group with a PN/AI syndrome than in the group without a PN/AI syndrome (10-year CIR 17.3% versus 21.2%, respectively [p = 0.0003]). The OS was improved in the group with a PN/AI syndrome compared to the group without a PN/AI syndrome (median OS 21.6 years versus 17.0 years, respectively [hazard ratio = 0.63, 95% confidence interval: 0.54–0.74, p < 0.0001]). However, in the multivariate model for recurrence-free survival and OS, PN/AI syndrome was not an independent prognostic factor. Discussion: Previously, there have been mixed data regarding the prognostic role of PN/AI syndromes for patients with TETs. Here, using the largest data set in the world for TETs, PN/AI syndromes were associated with favorable features (i.e., earlier stage and complete resection status) but were not an independent prognostic factor for patients with TETs.

AB - Introduction: Thymic epithelial tumors (TETs) are associated with paraneoplastic/autoimmune (PN/AI) syndromes. Myasthenia gravis is the most common PN/AI syndrome associated with TETs. Methods: The International Thymic Malignancy Interest Group retrospective database was examined to determine (1) baseline and treatment characteristics associated with PN/AI syndromes and (2) the prognostic role of PN/AI syndromes for patients with TETs. The competing risks model was used to estimate cumulative incidence of recurrence (CIR) and the Kaplan-Meier method was used to calculate overall survival (OS). A Cox proportional hazards model was used for multivariate analysis. Results: A total of 6670 patients with known PN/AI syndrome status from 1951 to 2012 were identified. PN/AI syndromes were associated with younger age, female sex, thymoma histologic type, earlier stage, and an increased rate of total thymectomy and complete resection status. There was a statistically significant lower CIR in the group with a PN/AI syndrome than in the group without a PN/AI syndrome (10-year CIR 17.3% versus 21.2%, respectively [p = 0.0003]). The OS was improved in the group with a PN/AI syndrome compared to the group without a PN/AI syndrome (median OS 21.6 years versus 17.0 years, respectively [hazard ratio = 0.63, 95% confidence interval: 0.54–0.74, p < 0.0001]). However, in the multivariate model for recurrence-free survival and OS, PN/AI syndrome was not an independent prognostic factor. Discussion: Previously, there have been mixed data regarding the prognostic role of PN/AI syndromes for patients with TETs. Here, using the largest data set in the world for TETs, PN/AI syndromes were associated with favorable features (i.e., earlier stage and complete resection status) but were not an independent prognostic factor for patients with TETs.

KW - Myasthenia gravis

KW - Paraneoplastic

KW - Thymic carcinoma

KW - Thymic epithelial tumor

KW - Thymoma

UR - http://www.scopus.com/inward/record.url?scp=85042447251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042447251&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2017.11.118

DO - 10.1016/j.jtho.2017.11.118

M3 - Article

VL - 13

SP - e33-e34

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 3

ER -